Upstate Active Clinical Trials

Study Title:

Prospective Study of Rapamycin for Treatment of SLE

What is the purpose of the study?

Purpose is to determine the safety and efficacy of rapamycin/sirolimus for treatment of disease manifestations and for normalizing relevant biomarkers of disease activity in patients with SLE; and to prospectively determine the mechanism of action of Rapamune in patients with SLE.

Upstate Institutional Review Board (IRB) Number:

231189

Study Phase:

N/A

Patient Age Group:

Adults

Principal Investigator:

Andras Perl, MD, PhD

Who is eligible?

SLE patients who satisfy the criteria for a definitive diagnosis and exhibit ongoing disease activity by SLEDAI greater than 4 will be included. Patietns whose disease activity is controlled by administration of corticsteroids, most commonly, 10 mg of prednisone or equivalent dose of another corticosteroid, will also be included. All subjects will be greater than 18 years of age.

What is involved if I participate?

  • How long is the study?
    40 SLE patients are needed and 40 Healthy Control Subjects.
  • Is transportation provided or reimbursed?
    Yes
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Sirolimus levels are checked; routine lab. and non-routine laboratory studies of relevant lupus biomarkers are done. Up to 100 ml of blood is drawn at each visit.

Where will the study take place?

UHCC/The Hill Medical Center / UH Pathology Laboratory/ Rheumatology Lab, 8299 Weiskotten Hall

Who can I contact for more information?

Name: Andras Perl, MD, PhD
Phone: 315-464-4194
Email: perla@upstate.edu

Return to Previous Page || Search Again